AbbVie (ABBV) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance

AbbVie (NYSE: ABBV) reported Q1 EPS of $2.65, $0.06 better than the analyst estimate of $2.59. Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.73 billion.

GUIDANCE:

AbbVie sees FY2026 EPS of $14.08-$14.28, versus the consensus of $14.21.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• PreveCeutical closes second tranche of private placement for $245,000
• Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders